Dousheng Wu

Title: Dousheng Wu: Innovator in Antitumor Therapies

Introduction

Dousheng Wu is a prominent inventor based in Guangdong, China. He has made significant contributions to the field of cancer treatment through his innovative research and development of novel therapeutic methods.

Latest Patents

Dousheng Wu holds a patent for a chimeric antigen receptor T (CAR-T) cell and its construction method, along with an associated antitumor drug. This patent introduces aquaporin 3 (AQP3) as a new anti-cancer target. AQP3 is notably expressed in both tumor cells and tumor stromal cells, facilitating the transport of water and glycerol. This mechanism aids in overcoming the physical barriers of tumors, allowing CAR-T cells to infiltrate effectively and target malignant cells. The CAR fusion protein developed in this patent shows promising results, particularly in treating AQP3-positive malignant tumors, including non-small cell lung cancer (NSCLC), while minimizing damage to normal tissues.

Career Highlights

Dousheng Wu is affiliated with Guangzhou Morui Pharmaceutical Technology Co., Ltd., where he continues to advance his research in cancer therapies. His work has garnered attention for its potential to improve treatment outcomes for patients with challenging malignancies.

Collaborations

Dousheng Wu collaborates with Yang Yang, contributing to the development of innovative cancer treatments. Their partnership enhances the research capabilities and accelerates the progress of their projects.

Conclusion

Dousheng Wu's contributions to the field of cancer treatment through his innovative patent demonstrate his commitment to advancing medical science. His work holds the potential to significantly impact the lives of patients battling cancer.